康西普治療公司
DE ˙ DB ˙ US2183521028
€63.98 ↑2.18 (3.53%)
2026-06-04
分享價格
SecurityDE:HTD / Corcept Therapeutics Incorporated
InstitutionNorges Bank
Latest Disclosed Ownership695,766 shares
Latest Disclosed Value $ 24,212,657
Norges Bank ownership in HTD / Corcept Therapeutics Incorporated

On February 10, 2026 - Norges Bank filed a 13F-HR form disclosing ownership of 695,766 shares of Corcept Therapeutics Incorporated (DE:HTD) valued at $47,047,697 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 0 shares of Corcept Therapeutics Incorporated. The current value of the position is $44,515,109 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-10 2025-12-31 13F CORCEPT THERAPEUTICS COM 218352102 695,766 695,766 24,213 0.0026
2025-11-13 2025-09-30 13F CORCEPT THERAPEUTICS COM 218352102 0 -981,577 -100.00 0 -100.00
2025-08-13 2025-06-30 13F CORCEPT THERAPEUTICS COM 218352102 981,577 132,680 15.63 72,048 -25.69 0.0090
2026-05-11 2025-03-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 848,897 14,306 1.71 96,961 130.56 0.0136
2025-02-12 2024-12-31 13F CORCEPT THERAPEUTICS COM 218352102 834,591 -425,387 -33.76 42,055 -27.88 0.0055
2025-11-12 2024-09-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 1,259,978 437,855 53.26 58,312 118.31 0.0081
2024-08-14 2024-06-30 13F CORCEPT THERAPEUTICS COM 218352102 822,123 0 0.00 26,711 28.98 0.0040
2025-05-14 2024-03-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 822,123 64,633 8.53 20,709 -15.83 0.0033
2024-02-09 2023-12-31 13F CORCEPT THERAPEUTICS COM 218352102 757,490 -95,490 -11.19 24,603 5.87 0.0043
2024-11-13 2023-09-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 852,980 120,000 16.37 23,239 42.50 0.0047
2024-08-14 2023-06-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 732,980 43,948 6.38 16,309 9.27 0.0032
2024-05-15 2023-03-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 689,032 -81,416 -10.57 14,924 -4.62 0.0033
2023-02-14 2022-12-31 13F CORCEPT THERAPEUTICS COM 218352102 770,448 57,221 8.02 15,648 -14.44 0.0038
2023-11-13 2022-09-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 713,227 19,402 2.80 18,287 10.84 0.0049
2023-08-14 2022-06-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 693,825 -86,897 -11.13 16,499 -6.15 0.0043
2023-05-12 2022-03-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 780,722 -42,880 -5.21 17,582 7.81 0.0038
2022-03-09 2021-12-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 823,602 -262,800 -24.19 16,307 -23.73 0.0034
2022-11-14 2021-09-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 1,086,402 127,727 13.32 21,380 1.37 0.0047
2022-08-15 2021-06-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 958,675 36,421 3.95 21,091 -3.87 0.0046
2022-05-09 2021-03-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 922,254 -282,244 -23.43 21,940 -30.37 0.0050
2021-03-02 2020-12-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 1,204,498 -163,214 -11.93 31,510 32.37 0.0074
2021-11-12 2020-09-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 1,367,712 -57,684 -4.05 23,805 -0.71 0.0063
2021-08-13 2020-06-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 1,425,396 369,889 35.04 23,975 91.04 0.0069
2021-05-07 2020-03-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 1,055,507 0 0.00 12,550 -1.74 0.0045
2020-03-03 2019-12-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 1,055,507 0 0.00 12,772 -14.40 0.0036
2020-11-13 2019-09-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 1,055,507 182,649 20.93 14,920 53.31 0.0046
2020-08-13 2019-06-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 872,858 167,533 23.75 9,732 17.54 0.0030
2020-05-11 2019-03-31 13F/A-2 CORCEPT THERAPEUTICS COM 218352102 705,325 0 0.00 8,280 -12.13 0.0027
2019-03-04 2018-12-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 705,325 0 0.00 9,423 -4.70 0.0035
2019-12-02 2018-09-30 13F/A-3 CORCEPT THERAPEUTICS COM 218352102 705,325 89,300 14.50 9,888 2.11 0.0032
2019-12-02 2018-09-30 13F/A-2 CORCEPT THERAPEUTICS COM 218352102 705,325 89,300 9,888 0.0032
2019-11-12 2018-09-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 705,325 89,300 9,888 0.0032
2019-08-12 2018-06-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 616,025 140,264 29.48 9,684 23.74 0.0033
2019-05-15 2018-03-31 13F/A-2 CORCEPT THERAPEUTICS COM 218352102 475,761 475,761 7,826 0.0028
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.